{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001739","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2021-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.443383+00:00","generated_at":"2026-06-29T04:53:18.952211+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rallybio reports Q2 net loss $11.1M; IPO gross proceeds $92.7M; pipeline on track for Phase 1 starts in Q1 2022","bullets":["Net loss of $11.1M ($2.80 per common unit) for Q2 2021, vs $4.9M in Q2 2020.","Cash and investments $112.7M as of June 30; August IPO added ~$83.2M net proceeds.","R&D expenses $6.8M in Q2 2021, up from $3.1M YoY, driven by RLYB212 and RLYB116 development.","Phase 1/2 data for RLYB211 (FNAIT) presented at ISTH; additional data expected Q4 2021.","Phase 1 studies of RLYB212 and RLYB116 planned to initiate in Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001739","json":"https://secwatch.observer/filing/0000950170-21-001739.json","markdown":"https://secwatch.observer/filing/0000950170-21-001739.md","text":"https://secwatch.observer/filing/0000950170-21-001739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017021001739/0000950170-21-001739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017021001739/rlyb-20210909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:53:18.952211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}